Home › Ovarian Cancer › Oklahoma
Ovarian Cancer clinical trials in Oklahoma
31 studies for Ovarian Cancer are looking for participants at sites in Oklahoma.
Cities in Oklahoma
The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Oct 5, 2026 · NCT06995898Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
All ages · All sexes · Updated Oct 5, 2026 · NCT05564377Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- OU Health, Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Oct 5, 2026 · NCT05739981The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- OU Health - Stephenson Cancer Center /ID# 277656, Oklahoma City
RecruitingPhase 2
Ages 18 and older · Women · Updated Oct 1, 2026 · NCT07024784Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT03564340A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213804Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007), Tulsa
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT07318558FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06303505A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0056), Tulsa
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06824467Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Oklahoma University Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Women · Updated Aug 26, 2026 · NCT05281471Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Aug 25, 2026 · NCT06276491A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Recruiting
Ages 35 to 50 · Women · Updated Aug 7, 2026 · NCT04251052A Study of DM002 in Patients With Advanced Solid Tumors
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06751329Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of Oklahoma - Health Sciences Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366Clinical Pre-screening Protocol for Ovarian Cancer
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingObservational study
Ages 18 and older · Women · Updated Jul 30, 2026 · NCT03877796A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Oklahoma Cancer Specialists and Research Institute, Tulsa
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT06161025Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- University of Oklahoma, Oklahoma City
RecruitingPhase 2
Ages 18 and older · Women · Updated Jul 14, 2026 · NCT04606914A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingHealthy volunteers welcome
Ages 50 to 74 · Women · Updated May 6, 2026 · NCT00539162A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 14, 2026 · NCT06234423A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 7, 2026 · NCT06999187CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Stephenson Cancer Center at the University of Oklahoma, Oklahoma City
RecruitingPhase 2
Ages 18 and older · Women · Updated Dec 23, 2025 · NCT06690775SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- Exelixis Clinical Site #13, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 5, 2025 · NCT05932862From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.